Oculis will attend be attending the 8th Annual Conference Biotech Showcase 2016 in San Francisco, CA. The conference takes place on January 11-13, 2016.
Oculis has been awarded a research grant from the Technology Development Fund.
Oculis today completed the formation of a new Scientific and Medical Advisory Board. The Advisory Board consists of five members with vast experience from ophthalmology and the pharmaceutical industry.
A new article has recently been published on the efficacy and safety of DexNP eye drops in DME patients, demonstrating that use of DexNP significantly improves visual acuity and decreases macular thickness in patients with DME.
Dr. Einar Stefansson, Oculis’ Chairman and Dr. Akihiro Ohira, member of Oculis’ Scientific and Medical Advisory Board, will both present at ISOPT Clinical meeting in Berlin results of pre-clinical studies involving the Oculis platform.
At Oculis’s AGM today, Dr. Joseph Markoff, Dr. James D. Pipkin and Dr. George Mooney were elected to Oculis’ Board of Directors.
Today, Oculis’ Board of Directors approved a new Organizational Chart for the Company reflecting the recent additions to the company’s management.
The results of a phase II studies in DME of Oculis’ most advanced drug candidate, DexNP will be presented at the 2015 ARVO meeting in Denver.
Results from a pilot study on DexNP, Oculis’ most advanced drug candidate, in uveitis, will be presented at the 2014 Annual Meeting of the American Academy of Ophthalmology held in Chicago, IL, 18-21 October 2014.